GlassScriptPhysician profile
Neeraj Sriram
NPI 1467849943
$9,297.94
in general payments reported to CMS, 2019-2025
38 companies · $1,960 in 2025
The $1,960 reported for 2025 was more than what 82% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.39 · 2020: $223 · 2021: $267 · 2022: $1,243 · 2023: $2,801 · 2024: $2,787 · 2025: $1,960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,560 · Travel and Lodging: $988.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,560.12 |
| Travel and Lodging | $988.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,345.60 | 2021-2025 | Intellis Adaptivestim, Vanta Adaptivestim |
| Boston Scientific Corporation | $2,252.11 | 2019-2025 | Wavewriter Alpha Prime 16, General - Therapies, Superion Indirect Decompression System |
| Collegium Pharmaceutical, INC. | $753.43 | 2022-2025 | Belbuca |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $584.18 | 2022-2025 | Relistor |
| Abbott Laboratories | $295.90 | 2024-2025 | Octrode, Eterna |
| Nalu Medical, INC. | $275.43 | 2022-2025 | Nalu Neurostimulation System |
| Stryker Corporation | $247.90 | 2025 | Optablate |
| Abbvie INC. | $238.08 | 2023-2025 | Ubrelvy, Qulipta |
| Pfizer INC. | $234.59 | 2023-2025 | |
| Nevro Corp. | $225.74 | 2021-2023 | Senza |
| Ibsa Pharma INC. | $183.91 | 2022-2025 | Tirosint, Licart, Licart |
| Azurity Pharmaceuticals, INC. | $164.07 | 2023-2025 | Horizant, Horizant |
| Forte Bio-Pharma LLC | $156.00 | 2022-2025 | Prolate, Tanlor, Nalocet |
| Lundbeck LLC | $152.82 | 2022-2023 | Vyepti |
| Protega Pharmaceutials INC | $134.70 | 2023 | Roxybond |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $133.07 | 2020-2022 | |
| Spr Therapeutics, INC | $107.73 | 2022-2025 | Sprint Pns System |
| Biohaven Pharmaceutical Holding Company LTD. | $103.40 | 2022 | |
| Stimwave Technologies Incorporated | $92.50 | 2020 | |
| Fidia Pharma USA INC. | $73.98 | 2023-2024 | Hymovis, Triluron, Hyalgan |
| Scilex Pharmaceuticals INC. | $66.77 | 2022-2024 | Ztlido |
| Vertex Pharmaceuticals Incorporated | $61.03 | 2025 | |
| Arbor Pharmaceuticals, INC. | $60.42 | 2022 | |
| Uswm, LLC | $44.70 | 2023 | Zimhi, Lucemyra |
| Vertos Medical, INC. | $42.91 | 2024 | Mild Device Kit |
| Alkermes, INC. | $39.98 | 2023-2024 | Vivitrol, Vivitrol |
| Spinal Simplicity, LLC | $36.32 | 2022-2023 | Ha Minuteman G3-R |
| Indivior INC. | $28.82 | 2023 | Sublocade |
| Saluda Medical Americas, INC. | $23.25 | 2025 | Evoke |
| Bioventus LLC | $21.54 | 2023 | Durolane |
| Valinor Pharma, LLC | $18.60 | 2025 | Movantik |
| Globus Medical, INC. | $16.20 | 2025 | Senza |
| Virtus Pharmaceuticals LLC | $15.70 | 2025 | Levorphanol Tartrate |
| Almatica Pharma LLC | $15.19 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.39 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.00 | 2022 | |
| Avanos Medical | $12.80 | 2022 | |
| Medtronic USA, INC. | $12.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neeraj Sriram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.